- In October 2024, Novaliq and Laboratoires Théa announced that, Vevizye received approval from Europen commission to market the product for treating dry eye disease in adults. It is the first and only water-free ciclosporin 0.1% eye drop solution to receive approval in Europe.
- In June 2024, Oculis reported Phase 2b positive results for licaminlimab, anti-TNFα eye drop, shows significant improvement in multiple DED signs. The drug, effective in patients with a specific TNFR1 genetic biomarker, demonstrated rapid and notable reduction in corneal inflammation. Licaminlimab was well tolerated with similar side effects to a vehicle.
- In May 2024, Nordic Pharma, Inc. launched LACRIFILL Canalicular Gel, a novel dry eye treatment cleared by the FDA. This cross-linked hyaluronic acid gel temporarily blocks tear drainage by occluding the canalicular system, allowing natural tears to bathe the eyes. Administered via a simple in-office procedure, it lasts for six months and is reimbursed under CPT code 68761. Nordic Pharma is showcasing LACRIFILL at Kiawah Eye 2024, highlighting its potential to enhance ophthalmic practices. Nordic Pharma, part of SEVER Life Sciences, focuses on specialty pharmaceuticals and has a global presence.
